JP2022532356A5 - - Google Patents

Info

Publication number
JP2022532356A5
JP2022532356A5 JP2021567963A JP2021567963A JP2022532356A5 JP 2022532356 A5 JP2022532356 A5 JP 2022532356A5 JP 2021567963 A JP2021567963 A JP 2021567963A JP 2021567963 A JP2021567963 A JP 2021567963A JP 2022532356 A5 JP2022532356 A5 JP 2022532356A5
Authority
JP
Japan
Application number
JP2021567963A
Other languages
Japanese (ja)
Other versions
JP2022532356A (ja
JPWO2020232173A5 (https=
JP7801132B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032754 external-priority patent/WO2020232173A1/en
Publication of JP2022532356A publication Critical patent/JP2022532356A/ja
Publication of JP2022532356A5 publication Critical patent/JP2022532356A5/ja
Publication of JPWO2020232173A5 publication Critical patent/JPWO2020232173A5/ja
Priority to JP2025133004A priority Critical patent/JP2025166108A/ja
Application granted granted Critical
Publication of JP7801132B2 publication Critical patent/JP7801132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021567963A 2019-05-14 2020-05-13 抗cd38抗体を投与して多発性骨髄腫を処置する方法 Active JP7801132B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133004A JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US62/847,825 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US62/860,739 2019-06-12
US201962899088P 2019-09-11 2019-09-11
US62/899,088 2019-09-11
EP20305223 2020-03-03
EP20305223.8 2020-03-03
PCT/US2020/032754 WO2020232173A1 (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133004A Division JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Publications (4)

Publication Number Publication Date
JP2022532356A JP2022532356A (ja) 2022-07-14
JP2022532356A5 true JP2022532356A5 (https=) 2023-05-22
JPWO2020232173A5 JPWO2020232173A5 (https=) 2023-05-22
JP7801132B2 JP7801132B2 (ja) 2026-01-16

Family

ID=71094805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567963A Active JP7801132B2 (ja) 2019-05-14 2020-05-13 抗cd38抗体を投与して多発性骨髄腫を処置する方法
JP2025133004A Pending JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133004A Pending JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Country Status (15)

Country Link
US (1) US20210171650A1 (https=)
EP (1) EP3969004A1 (https=)
JP (2) JP7801132B2 (https=)
KR (1) KR20220008305A (https=)
CN (2) CN114080233A (https=)
AU (1) AU2020274169A1 (https=)
BR (1) BR112021022503A2 (https=)
CA (1) CA3140034A1 (https=)
CO (1) CO2021016606A2 (https=)
IL (1) IL287832A (https=)
MA (1) MA55967A (https=)
MX (1) MX2021013910A (https=)
SG (1) SG11202112513YA (https=)
TW (1) TW202108624A (https=)
WO (1) WO2020232173A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
TW202019962A (zh) * 2018-07-10 2020-06-01 法商賽諾菲公司 標靶CD38及TGF-β的組合療法
CN113993543B (zh) * 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
AU2022253256A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd38-targeted antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US11939390B2 (en) * 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022532356A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
JP2023550311A5 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)